| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
|
Doggen, Kris
|
|
|
|
5 |
p. 481-497
|
artikel
|
| 2 |
A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France
|
Drummond, Michael
|
|
2014
|
|
5 |
p. 509-520
|
artikel
|
| 3 |
Adapting the CHEERS Statement for Reporting Cost-Benefit Analysis
|
Sanghera, Sabina
|
|
2015
|
|
5 |
p. 533-534
|
artikel
|
| 4 |
A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet
|
Stollenwerk, Björn
|
|
2018
|
|
5 |
p. 603-612
|
artikel
|
| 5 |
An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis
|
Franklin, Matthew
|
|
2019
|
|
5 |
p. 631-643
|
artikel
|
| 6 |
Anti-Inflammatory Medication Adherence, Healthcare Utilization and Expenditures among Medicaid and Children’s Health Insurance Program Enrollees with Asthma
|
Herndon, Jill Boylston
|
|
2012
|
|
5 |
p. 397-412
|
artikel
|
| 7 |
A Review and Classification of Approaches for Dealing with Uncertainty in Multi-Criteria Decision Analysis for Healthcare Decisions
|
Broekhuizen, Henk
|
|
2015
|
|
5 |
p. 445-455
|
artikel
|
| 8 |
Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?
|
Woods, Beth
|
|
2015
|
|
5 |
p. 427-433
|
artikel
|
| 9 |
Assessments of the Value of New Interventions Should Include Health Equity Impact
|
Jansen, Jeroen P.
|
|
|
|
5 |
p. 489-495
|
artikel
|
| 10 |
Authors’ Reply to Gandjour: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation”
|
Wagner, Monika
|
|
2017
|
|
5 |
p. 605-606
|
artikel
|
| 11 |
Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?
|
O’Mahony, James F.
|
|
2019
|
|
5 |
p. 627-630
|
artikel
|
| 12 |
Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland–Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data
|
Madan, Jason
|
|
2017
|
|
5 |
p. 549-559
|
artikel
|
| 13 |
Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
|
Claxton, Lindsay
|
|
2018
|
|
5 |
p. 645-654
|
artikel
|
| 14 |
Changes in Antipsychotic Medication Use after Implementation of a Medicaid Mental Health Carve-Out in the US
|
Robst, John
|
|
2012
|
|
5 |
p. 387-396
|
artikel
|
| 15 |
Comment on: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation”
|
Gandjour, Afschin
|
|
2017
|
|
5 |
p. 603-604
|
artikel
|
| 16 |
Complex Valuation: Applying Ideas from the Complex Intervention Framework to Valuation of a New Measure for End-of-Life Care
|
Coast, Joanna
|
|
2015
|
|
5 |
p. 499-508
|
artikel
|
| 17 |
Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches
|
Hughes, Dyfrig
|
|
2016
|
|
5 |
p. 447-461
|
artikel
|
| 18 |
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
|
Husereau, Don
|
|
2013
|
|
5 |
p. 361-367
|
artikel
|
| 19 |
Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
|
Claxton, Lindsay
|
|
2018
|
|
5 |
p. 739
|
artikel
|
| 20 |
Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
|
Goswami, Hardik
|
|
|
|
5 |
p. 605
|
artikel
|
| 21 |
Correction to: Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study
|
Franklin, Matthew
|
|
2019
|
|
5 |
p. 741
|
artikel
|
| 22 |
Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Grimm, Sabine E.
|
|
|
|
5 |
p. 575
|
artikel
|
| 23 |
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review
|
D’Angiolella, Lucia Sara
|
|
2018
|
|
5 |
p. 567-589
|
artikel
|
| 24 |
Cost and Cost Effectiveness of Vaginal Progesterone Gel in Reducing Preterm Birth: An Economic Analysis of the PREGNANT Trial
|
Pizzi, Laura T.
|
|
2014
|
|
5 |
p. 467-478
|
artikel
|
| 25 |
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
|
Kim, Yong-Jin
|
|
|
|
5 |
p. 537-548
|
artikel
|
| 26 |
Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy
|
Ruggeri, M.
|
|
2018
|
|
5 |
p. 625-636
|
artikel
|
| 27 |
Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium
|
Annemans, Lieven
|
|
2014
|
|
5 |
p. 479-493
|
artikel
|
| 28 |
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
|
Kobayashi, Taku
|
|
|
|
5 |
p. 589-604
|
artikel
|
| 29 |
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland
|
Schur, Nadine
|
|
|
|
5 |
p. 563-577
|
artikel
|
| 30 |
Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States
|
Guy, Holly
|
|
2018
|
|
5 |
p. 701-714
|
artikel
|
| 31 |
Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s Disease
|
Getsios, Denis
|
|
2010
|
|
5 |
p. 411-427
|
artikel
|
| 32 |
Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study
|
Coyle, Kathryn
|
|
2016
|
|
5 |
p. 509-520
|
artikel
|
| 33 |
Cost Effectiveness of Selective Decontamination of the Digestive Tract in Liver Transplant Patients
|
van Enckevort, Petra J.
|
|
|
|
5 |
p. 523-530
|
artikel
|
| 34 |
Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer
|
Millar, J. Alasdair
|
|
2007
|
|
5 |
p. 429-442
|
artikel
|
| 35 |
Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review
|
Ruiz-Negrón, Natalia
|
|
2019
|
|
5 |
p. 669-688
|
artikel
|
| 36 |
Cost Effectiveness of Treatments for Inflammatory Bowel Disease
|
Bodger, Keith
|
|
|
|
5 |
p. 387-401
|
artikel
|
| 37 |
Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches
|
Elbasha, Elamin H.
|
|
|
|
5 |
p. 497-507
|
artikel
|
| 38 |
Cost-Effectiveness Thresholds: the Past, the Present and the Future
|
Thokala, Praveen
|
|
2018
|
|
5 |
p. 509-522
|
artikel
|
| 39 |
Cost of Acute Stroke Care for Patients with Atrial Fibrillation Compared with Those in Sinus Rhythm
|
Ali, Ali N.
|
|
2015
|
|
5 |
p. 511-520
|
artikel
|
| 40 |
Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature Review
|
Bozzani, Fiammetta M.
|
|
|
|
5 |
p. 467-480
|
artikel
|
| 41 |
Costs of a Community Pharmacist-Led Medicines Management Service for Patients with Coronary Heart Disease in England
|
Scott, Anthony
|
|
2007
|
|
5 |
p. 397-411
|
artikel
|
| 42 |
Cost-Utility Analysis of Intravenous Immunoglobulin for the Treatment of Steroid-Refractory Dermatomyositis in Thailand
|
Bamrungsawad, Naruemon
|
|
2015
|
|
5 |
p. 521-531
|
artikel
|
| 43 |
Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities
|
Keeney, Edna
|
|
2018
|
|
5 |
p. 523-532
|
artikel
|
| 44 |
Direct and Indirect Costs of Non-Vertebral Fracture Patients with Osteoporosis in the US
|
Pike, Crystal
|
|
2010
|
|
5 |
p. 395-409
|
artikel
|
| 45 |
Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review
|
Palacios, Alfredo
|
|
|
|
5 |
p. 485-502
|
artikel
|
| 46 |
Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial
|
Finch, Aureliano Paolo
|
|
2018
|
|
5 |
p. 689-699
|
artikel
|
| 47 |
Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review
|
Strouphauer, Emily R.
|
|
|
|
5 |
p. 499-527
|
artikel
|
| 48 |
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
|
Huang, Min
|
|
|
|
5 |
p. 519-558
|
artikel
|
| 49 |
Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature
|
Frey, Simon
|
|
2015
|
|
5 |
p. 479-498
|
artikel
|
| 50 |
Economic Content in Medical Journal Advertisements for Medical Devices and Prescription Drugs
|
Ackerly, D. Clay
|
|
2010
|
|
5 |
p. 429-438
|
artikel
|
| 51 |
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
|
Wisløff, Torbjørn
|
|
2018
|
|
5 |
p. 591-601
|
artikel
|
| 52 |
Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review
|
Ruggeri, Matteo
|
|
|
|
5 |
p. 473-484
|
artikel
|
| 53 |
Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study
|
Franklin, Matthew
|
|
2017
|
|
5 |
p. 561-573
|
artikel
|
| 54 |
Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review
|
Brockbank, James
|
|
2017
|
|
5 |
p. 517-535
|
artikel
|
| 55 |
Economic Evaluations with Agent-Based Modelling: An Introduction
|
Chhatwal, Jagpreet
|
|
2015
|
|
5 |
p. 423-433
|
artikel
|
| 56 |
Economic Impact of Providing Workplace Influenza Vaccination
|
Burckel, Emmanuel
|
|
|
|
5 |
p. 563-576
|
artikel
|
| 57 |
EQ-5D-5L Valuation for the Malaysian Population
|
Shafie, Asrul Akmal
|
|
2018
|
|
5 |
p. 715-725
|
artikel
|
| 58 |
EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria
|
Hawe, Emma
|
|
2016
|
|
5 |
p. 521-527
|
artikel
|
| 59 |
Erratum to: Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease
|
Mittmann, Nicole
|
|
2011
|
|
5 |
p. 414
|
artikel
|
| 60 |
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Carroll, Christopher
|
|
2017
|
|
5 |
p. 537-547
|
artikel
|
| 61 |
Exploring Structural Uncertainty in Model-Based Economic Evaluations
|
Haji Ali Afzali, Hossein
|
|
2015
|
|
5 |
p. 435-443
|
artikel
|
| 62 |
Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults
|
Rowen, Donna
|
|
|
|
5 |
p. 479-488
|
artikel
|
| 63 |
Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best–Worst Scaling
|
Dalziel, Kim
|
|
|
|
5 |
p. 499-513
|
artikel
|
| 64 |
Fibromyalgia: Disease Synopsis, Medication Cost Effectiveness and Economic Burden
|
Skaer, Tracy L.
|
|
2014
|
|
5 |
p. 457-466
|
artikel
|
| 65 |
Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Pouwels, Xavier G. L. V.
|
|
|
|
5 |
p. 431-441
|
artikel
|
| 66 |
Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal
|
Armstrong, Nigel
|
|
2013
|
|
5 |
p. 415-425
|
artikel
|
| 67 |
Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach
|
Mau, Lih-Wen
|
|
|
|
5 |
p. 515-526
|
artikel
|
| 68 |
Health Economic and Infectious Disease Modelling
|
Anonychuk, Andrea
|
|
|
|
5 |
p. 367-369
|
artikel
|
| 69 |
Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now
|
Zhang, Wei
|
|
2014
|
|
5 |
p. 425-427
|
artikel
|
| 70 |
Health Utilities Using the EQ-5D in Studies of Cancer
|
Pickard, A. Simon
|
|
2007
|
|
5 |
p. 365-384
|
artikel
|
| 71 |
Hispa-NICE: A Pipe Dream or a Realistic and Necessary Initiative?
|
Antoñanzas, Fernando
|
|
|
|
5 |
p. 481-483
|
artikel
|
| 72 |
How Much Should the NHS Pay for a QALY?
|
Haycox, Alan
|
|
2013
|
|
5 |
p. 357-359
|
artikel
|
| 73 |
How to Predict Drug Expenditure: A Markov Model Approach with Risk Classes
|
Hofbauer-Milan, Valeska
|
|
|
|
5 |
p. 561-572
|
artikel
|
| 74 |
How to Select the Right Cost-Effectiveness Model?
|
Haalen, H. G. M. van
|
|
2014
|
|
5 |
p. 429-442
|
artikel
|
| 75 |
HTA Barriers for Conditional Approval Drugs
|
Mills, Mackenzie
|
|
|
|
5 |
p. 529-545
|
artikel
|
| 76 |
Human Papillomavirus Vaccination Is Not Exclusively a Matter of Price
|
Capone, Alessandro
|
|
2012
|
|
5 |
p. 443-444
|
artikel
|
| 77 |
Is Individualized Medicine More Cost-Effective? A Systematic Review
|
Hatz, Maximilian H. M.
|
|
2014
|
|
5 |
p. 443-455
|
artikel
|
| 78 |
Issues in the Economic Evaluation of Influenza Vaccination by Injection of Healthy Working Adults in the US
|
Hogan, Thomas J.
|
|
2012
|
|
5 |
p. 355-371
|
artikel
|
| 79 |
Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States
|
Simpson, Kit N.
|
|
|
|
5 |
p. 427-444
|
artikel
|
| 80 |
Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States
|
Simpson, Kit N.
|
|
2013
|
|
5 |
p. 427-444
|
artikel
|
| 81 |
Making Implicit Assumptions Explicit in the Costing of Informal Care: The Case of Head and Neck Cancer in Ireland
|
Hanly, Paul
|
|
2017
|
|
5 |
p. 591-601
|
artikel
|
| 82 |
Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals
|
Pink, Joshua
|
|
2012
|
|
5 |
p. 413-429
|
artikel
|
| 83 |
Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Systematic Literature Review
|
Dritsaki, Melina
|
|
2017
|
|
5 |
p. 501-515
|
artikel
|
| 84 |
Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology
|
Majer, Istvan M.
|
|
2019
|
|
5 |
p. 727-737
|
artikel
|
| 85 |
Modelling the Epidemiology of Infectious Diseases for Decision Analysis
|
Jit, Mark
|
|
|
|
5 |
p. 371-386
|
artikel
|
| 86 |
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Grimm, Sabine E.
|
|
|
|
5 |
p. 509-518
|
artikel
|
| 87 |
Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness
|
Neves, Manuel
|
|
|
|
5 |
p. 579-587
|
artikel
|
| 88 |
New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes
|
Varnava, Alice
|
|
2018
|
|
5 |
p. 613-624
|
artikel
|
| 89 |
Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Grimm, Sabine E.
|
|
2018
|
|
5 |
p. 655-667
|
artikel
|
| 90 |
Optimal Global Value of Information Trials: Better Aligning Manufacturer and Decision Maker Interests and Enabling Feasible Risk Sharing
|
Eckermann, Simon
|
|
2013
|
|
5 |
p. 393-401
|
artikel
|
| 91 |
Pharmaceutical Price Schemes in Europe: Time for a ‘Continental’ One?
|
Garattini, Livio
|
|
2016
|
|
5 |
p. 423-426
|
artikel
|
| 92 |
Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.
|
Baal, Pieter van
|
|
2013
|
|
5 |
p. 369-373
|
artikel
|
| 93 |
Pharmacoeconomics of Bisphosphonates for Skeletal-Related Event Prevention in Metastatic Non-Breast Solid Tumours
|
Carter, John A.
|
|
2012
|
|
5 |
p. 373-386
|
artikel
|
| 94 |
Pharmacy Benefit Management Companies: Do They Create Value in the US Healthcare System?
|
Lyles, Alan
|
|
2017
|
|
5 |
p. 493-500
|
artikel
|
| 95 |
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK
|
Zhou, Junwen
|
|
|
|
5 |
p. 547-559
|
artikel
|
| 96 |
Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
|
Schawo, Saskia
|
|
2015
|
|
5 |
p. 489-509
|
artikel
|
| 97 |
Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration
|
Husereau, Don
|
|
2015
|
|
5 |
p. 535-536
|
artikel
|
| 98 |
Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Cooper, Keith
|
|
2018
|
|
5 |
p. 545-553
|
artikel
|
| 99 |
Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study
|
Kruse, Christopher
|
|
|
|
5 |
p. 601-615
|
artikel
|
| 100 |
RETRACTED ARTICLE: The EQ-5D-5L Valuation Study in Egypt
|
Al Shabasy, Sahar A.
|
|
|
|
5 |
p. 549-561
|
artikel
|
| 101 |
Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia
|
Sorich, Michael J.
|
|
2013
|
|
5 |
p. 377-391
|
artikel
|
| 102 |
Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma
|
Greenhalgh, Janette
|
|
2013
|
|
5 |
p. 403-413
|
artikel
|
| 103 |
Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Pandor, Abdullah
|
|
2015
|
|
5 |
p. 463-477
|
artikel
|
| 104 |
Rotavirus Vaccine RIX4414 (Rotarix™)
|
Plosker, Greg L.
|
|
|
|
5 |
p. 439-454
|
artikel
|
| 105 |
Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements
|
Johansen, Pierre
|
|
|
|
5 |
p. 485-497
|
artikel
|
| 106 |
Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs
|
Ghabri, Salah
|
|
|
|
5 |
p. 459-471
|
artikel
|
| 107 |
Systematic Review of Humanistic and Economic Burden of Symptomatic Chronic Obstructive Pulmonary Disease
|
Srivastava, Kunal
|
|
2015
|
|
5 |
p. 467-488
|
artikel
|
| 108 |
The Australian Managed Entry Scheme: Are We Getting it Right?
|
Tuffaha, Haitham W.
|
|
2018
|
|
5 |
p. 555-565
|
artikel
|
| 109 |
The Authors’ Reply
|
Garattini, Livio
|
|
2012
|
|
5 |
p. 444-445
|
artikel
|
| 110 |
The Authors’ Reply to van Baal et al.: “Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.”
|
Grima, Daniel T.
|
|
2013
|
|
5 |
p. 375-376
|
artikel
|
| 111 |
The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence
|
Wade, Ros
|
|
2015
|
|
5 |
p. 457-466
|
artikel
|
| 112 |
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England
|
Chaudhuri, K. Ray
|
|
|
|
5 |
p. 559-574
|
artikel
|
| 113 |
The Cost of Dementia in Europe
|
Jönsson, Linus
|
|
2009
|
|
5 |
p. 391-403
|
artikel
|
| 114 |
The Cost of Uncontrolled Blood Pressure in Australian General Practice: A Modelling Study Using Electronic Health Records (MedicineInsight)
|
Roseleur, Jacqueline
|
|
|
|
5 |
p. 573-587
|
artikel
|
| 115 |
The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies
|
Refoios Camejo, Rodrigo
|
|
2013
|
|
5 |
p. 445-454
|
artikel
|
| 116 |
The Impact of Co-Morbidity Burden on Preference-Based Health-Related Quality of Life in the United States
|
Sullivan, Patrick W.
|
|
2012
|
|
5 |
p. 431-442
|
artikel
|
| 117 |
The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling
|
Shafie, Asrul Akmal
|
|
2017
|
|
5 |
p. 575-589
|
artikel
|
| 118 |
The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling
|
Shafie, Asrul Akmal
|
|
|
|
5 |
p. 575-589
|
artikel
|
| 119 |
The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD)
|
Wahlqvist, Peter
|
|
2007
|
|
5 |
p. 385-396
|
artikel
|
| 120 |
Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Pouwels, Xavier G. L. V.
|
|
2018
|
|
5 |
p. 533-543
|
artikel
|
| 121 |
Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer
|
Hall, Peter S.
|
|
2011
|
|
5 |
p. 415-432
|
artikel
|
| 122 |
Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening
|
Keeney, Edna
|
|
|
|
5 |
p. 589-600
|
artikel
|
| 123 |
Utility Decrements Associated with Adult Overweight and Obesity in Australia: A Systematic Review and Meta-Analysis
|
Carrello, Joseph
|
|
|
|
5 |
p. 503-519
|
artikel
|
| 124 |
Valuation of EQ-5D-3L Health States in Singapore: Modeling of Time Trade-Off Values for 80 Empirically Observed Health States
|
Luo, Nan
|
|
2014
|
|
5 |
p. 495-507
|
artikel
|
| 125 |
Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension
|
Wu, Jing
|
|
|
|
5 |
p. 521-535
|
artikel
|
| 126 |
Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment
|
Angelis, Aris
|
|
2016
|
|
5 |
p. 435-446
|
artikel
|
| 127 |
Valuing Healthcare Goods and Services: A Systematic Review and Meta-Analysis on the WTA-WTP Disparity
|
Rotteveel, Adriënne H.
|
|
|
|
5 |
p. 443-458
|
artikel
|
| 128 |
We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can
|
Tapper, Elliot B.
|
|
|
|
5 |
p. 427-429
|
artikel
|
Tijdschrift beschrijving